Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

ARTICLES

Beyond intended use: PSA, hCG as tumor markers

June 2025—At Corewell Health William Beaumont University Hospital in Royal Oak, Mich., the PSA test volume for men ages 40 to 49 is significant—about 150 samples per month, or 10 percent of the laboratory’s total PSA testing volume. But with no PSA assay approved for men under age 50, the laboratory set out to validate its Abbott Architect assay for this age group as a laboratory-developed test. Qian (Katie) Sun, PhD, D(ABCC), technical director of automated chemistry and urinalysis, explained how it was done in an ADLM session last year on designing validation protocols for off-label use of tumor markers in diverse patient populations. She also spoke about the use of hCG immunoassays as a tumor marker in gestational trophoblastic disease and select germ cell tumors.

Focus on instruments: scalability, timelines, and IT

June 2025—Chemistry and immunoassay analyzers—the customer input that shapes their development and the laboratory acquisition process and timeline. That and more, including the IT obstacles and solutions, were the focus of a roundtable, led by CAP TODAY publisher Bob McGonnagle. He spoke with Moira Larsen, MD, MBA, of MedStar Health; Joe Baker of Baylor Scott & White; and representatives of Beckman Coulter, Roche, and Siemens Healthineers. Read about their April 15 online conversation.

Taking on low, ultralow HER2 breast cancer

May 2025—Since the hunt began to identify low levels of HER2 in metastatic breast cancers, the action has revealed itself like the plot of a Henry James novel: Nothing much happens. Also, a lot happens. And each narrative thread is conveyed in hard-to-parse language. The goal has been to qualify patients for the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which was shown in the Destiny-Breast04 trial to significantly improve survival in so-called HER2-low cases. Immunohistochemistry assays were designed to identify strongly positive cases, however, and thus not useful for those at the 0 and 1+ end of the spectrum. Now, several years after the presentation of the D-B04 results at the ASCO 2022 annual meeting, which launched the low-end ship, pathologists and oncologists are adjusting to the implications of the most recent Destiny trial, D-B06. In late January, the FDA approved the drug Enhertu for HER2-low or HER2-ultralow cases, as well as the Ventana Pathway HER2 (4B5) companion diagnostic for assessing these lower levels of HER2 in patients with metastatic breast cancer.

Misses, hits in urine drug test interpretation

May 2025—When a physician or health care professional isn’t sure how to interpret a urine drug test result, Christine Snozek, PhD, codirector of clinical chemistry at Mayo Clinic in Arizona, always hopes they’ll call the laboratory for help—especially if the alternative is paging Dr. Google.

Canada’s path to targeted antenatal RhIG prophylaxis

May 2025—Fetal RhD prediction by genotyping can prevent unnecessary RhD treatment in some patients and conserve anti-D immunoglobulin. Other countries long ago adopted a targeted antenatal approach to RhD genotyping, and in Canada change is underway.

Close-up on StatLab’s portfolio and plans

May 2025—Despite its extensive portfolio and multiple manufacturing sites, simplicity seems to be at the heart of StatLab, thanks to its self-manufacturing approach. Four years ago, StatLab was primarily a distributor of medical products and manufacturer of a select few. Acquisitions, investment, and a change in the company’s profile came with new ownership, and the company, based in McKinney, Tex., is now “a full-fledged manufacturer across the entire histology portfolio,” says Joe Bernardo, chairman of the board of StatLab.

Granulomas on FNA: recognizing and ruling out malignancy

May 2025—Granulomas are organized clusters of immune cells that form as part of the body’s chronic inflammatory response, typically triggered by persistent antigens, chronic infections, or immune dysregulation. They develop when macrophages are activated, transforming into epithelioid histiocytes and multinucleated giant cells (MGC) in response to ongoing immune stimulation. Granulomas are usually surrounded by T lymphocytes, fibroblasts, and extracellular matrix components. While granulomas are most often associated with infections or autoimmune conditions like sarcoidosis, they can arise in a variety of other processes, including malignancy.

For myeloid malignancies, how WHO-HEM5 and ICC differ

May 2025—How the World Health Organization fifth edition of hematolymphoid tumors and the International Consensus Classification differ for myeloid malignancies was highlighted in cases presented in a CAP24 session last fall. Sanam Loghavi, MD, associate professor of pathology and laboratory medicine, Department of Hematopathology, University of Texas MD Anderson Cancer Center, spoke of myelodysplastic neoplasms/syndromes (MDS) with defining genetic abnormalities and the allelic state of TP53 in MDS, among other things. (Kamran M. Mirza, MD, PhD, of the University of Michigan, co-presented.)

Claudin 18.2: a new therapeutic target: What are the implications for cytopathologists?

May 2025—Claudin 18.2 (CLDN18.2), an isoform of claudin-18, is a transmembrane tight junction protein essential for maintaining barrier function and cell polarity in normal gastric and pancreatic epithelium. In malignant epithelial cells, the loss of polarity exposes the CLDN18.2 epitope, leading to its increased expression in gastric and pancreatic adenocarcinomas. CLDN18.2 has drawn attention as a therapeutic target, particularly with the development of the monoclonal IgG antibody zolbetuximab (Vyloy, Astellas Pharma). Zolbetuximab exerts its antitumor effects via both antibody-dependent and complement-mediated cytotoxicity and has demonstrated significantly improved progression-free and overall survival when combined with standard chemotherapy in two pivotal phase three clinical trials (SPOTLIGHT and GLOW). These data validated CLDN18.2 as a promising target in advanced, HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma.

MARKETPLACE

TRENDING